Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Syndax Pharmaceuticals (SNDX) Receivables - Other (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Receivables - Other for 12 consecutive years, with $24.7 million as the latest value for Q1 2026.

  • For Q1 2026, Receivables - Other rose 139.81% year-over-year to $24.7 million; the TTM value through Mar 2026 reached $24.7 million, up 139.81%, while the annual FY2025 figure was $28.1 million, 2061.54% up from the prior year.
  • Receivables - Other hit $24.7 million in Q1 2026 for Syndax Pharmaceuticals, up from $2.1 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $24.7 million in Q1 2026 and bottomed at $158000.0 in Q1 2022.
  • Average Receivables - Other over 5 years is $4.3 million, with a median of $2.0 million recorded in 2024.
  • Year-over-year, Receivables - Other skyrocketed 2925.87% in 2022 and then tumbled 95.92% in 2023.
  • Syndax Pharmaceuticals' Receivables - Other stood at $583000.0 in 2022, then soared by 110.46% to $1.2 million in 2023, then surged by 196.25% to $3.6 million in 2024, then tumbled by 40.96% to $2.1 million in 2025, then surged by 1050.98% to $24.7 million in 2026.
  • According to Business Quant data, Receivables - Other over the past three periods came in at $24.7 million, $2.1 million, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.